Drug intelligence / Profile preview

BIOD-125

Development stage: Phase 1
Lead developer: Ipsen
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

BIOD-125 is an ultra-rapid-acting formulation of recombinant human insulin (RHI) developed by Biodel Inc. It is designed to improve upon previous formulations by maintaining ultra-rapid absorption while enhancing injection site toleration. BIOD-125 was compared to Humalog in a Phase 1 clinical trial, demonstrating faster absorption rates and improved toleration profiles[1][4][6].

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on BIOD-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOD-125.

Explore the full profile